Success Metrics

Clinical Success Rate
87.5%

Based on 21 completed trials

Completion Rate
88%(21/24)
Active Trials
9(21%)
Results Posted
67%(14 trials)
Terminated
3(7%)

Phase Distribution

Ph phase_4
5
12%
Ph phase_1
1
2%
Ph not_applicable
3
7%
Ph phase_2
19
44%
Ph phase_3
12
28%

Phase Distribution

1

Early Stage

19

Mid Stage

17

Late Stage

Phase Distribution40 total trials
Phase 1Safety & dosage
1(2.5%)
Phase 2Efficacy & side effects
19(47.5%)
Phase 3Large-scale testing
12(30.0%)
Phase 4Post-market surveillance
5(12.5%)
N/ANon-phased studies
3(7.5%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

87.5%

21 of 24 finished

Non-Completion Rate

12.5%

3 ended early

Currently Active

9

trials recruiting

Total Trials

43

all time

Status Distribution
Active(13)
Completed(21)
Terminated(3)
Other(6)

Detailed Status

Completed21
Recruiting6
unknown6
Not yet recruiting4
Active, not recruiting3
Terminated3

Development Timeline

Analytics

Development Status

Total Trials
43
Active
9
Success Rate
87.5%
Most Advanced
Phase 4

Trials by Phase

Phase 11 (2.5%)
Phase 219 (47.5%)
Phase 312 (30.0%)
Phase 45 (12.5%)
N/A3 (7.5%)

Trials by Status

completed2149%
recruiting614%
active_not_recruiting37%
not_yet_recruiting49%
terminated37%
unknown614%

Recent Activity

Clinical Trials (43)

Showing 20 of 43 trialsScroll for more
NCT04630145Phase 2

A Study of Bedaquiline Administered as Part of a Treatment Regimen With Clarithromycin and Ethambutol in Adult Patients With Treatment-refractory Mycobacterium Avium Complex-lung Disease (MAC-LD)

Completed
NCT06192160Phase 2

Trial of Novel Regimens for the Treatment of Pulmonary Tuberculosis

Recruiting
NCT06253715Phase 3

Shortened Regimen for Drug-susceptible TB in Children

Recruiting
NCT04930744Phase 2

Safety and Tolerability of Metformin in People With Tuberculosis (TB) and Human Immunodeficiency Virus (HIV)

Completed
NCT07485010Phase 2

Testing a Novel Combination Treatment (Arm D) Versus Standard of Care for Intensive Phase Treatment for Mycobacterium Abscessus Pulmonary Disease in People With or Without Cystic Fibrosis in the Finding the Optimal Regimen for Mycobacterium Abscessus Treatment (FORMaT) Adaptive Platform Trial

Not Yet Recruiting
NCT05556746Phase 2

Ultra-Short Course Bedaquiline, Clofazimine, Pyrazinamide and Delamanid Versus Standard Therapy for Drug-Susceptible TB

Active Not Recruiting
NCT04677569Phase 3

Study to Evaluate ALIS (Amikacin Liposome Inhalation Suspension) in Participants With Nontuberculous Mycobacterial Lung Infection Caused by Mycobacterium Avium Complex

Completed
NCT03672630Phase 2

Comparison of Two- Versus Three-antibiotic Therapy for Pulmonary Mycobacterium Avium Complex Disease

Completed
NCT00042289

Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy

Completed
NCT03236987Phase 3

CLArithromycin Versus AZIthromycin in the Treatment of Mycobacterium Avium Complex (MAC) Lung Infections

Recruiting
NCT05766267Phase 2

Short-course Regimens for the Treatment of Pulmonary Tuberculosis

Active Not Recruiting
NCT02563327Phase 3

Pharmacokinetic and Pharmacodynamic Study of High-Dose Rifapentine and Moxifloxacin for Treatment of Tuberculosis

Completed
NCT07084402Phase 4

Short-term Bactericidal Effect of Contezolid in MAC-PD

Recruiting
NCT04311502Phase 2

Clofazimine- and Rifapentine-Containing Treatment Shortening Regimens in Drug-Susceptible Tuberculosis: The CLO-FAST Study

Terminated
NCT04921943Phase 4

Hypertonic Saline for MAC

Recruiting
NCT04310930Phase 2

Finding the Optimal Regimen for Mycobacterium Abscessus Treatment

Recruiting
NCT06917495Phase 2

Short-Course Anti-tuberculosis Regimens for Mild Spinal Tuberculosis

Not Yet Recruiting
NCT06081361Phase 3

Innovating Shorter, All- Oral, Precised, Individualized Treatment Regimen for Rifampicin Resistant Tuberculosis:Contezolid, Delamanid and Bedaquiline Cohort

Active Not Recruiting
NCT04677543Phase 3

Validation of Patient Reported Outcome Measures in Participants With Nontuberculous Mycobacterial Lung Infection Caused by Mycobacterium Avium Complex

Completed
NCT05966688Phase 1

A Study to Evaluate the Effect of Co-administration on the Pharmacokinetics of SPR720, Azithromycin, and Ethambutol in Healthy Participants

Completed

Drug Details

Intervention Type
DRUG
Total Trials
43